Bellevue Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bellevue Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30	Closed	-$2.5K	–	508
2024 Q4	$2.5K	Hold	30	–	–	﹤0.01%	421
2024 Q3	$2.19K	Hold	30	–	–	﹤0.01%	406
2024 Q2	$2.05K	Hold	30	–	–	﹤0.01%	405
2024 Q1	$2.08K	Hold	30	–	–	﹤0.01%	406
2023 Q4	$2.15K	Hold	30	–	–	﹤0.01%	396
2023 Q3	$1.56K	Hold	30	–	–	﹤0.01%	414
2023 Q2	$1.9K	Hold	30	–	–	﹤0.01%	409
2023 Q1	$1.62K	Hold	30	–	–	﹤0.01%	441
2022 Q4	$1.59K	Hold	30	–	–	﹤0.01%	429
2022 Q3	$1K	Hold	30	–	–	﹤0.01%	490
2022 Q2	$2K	Hold	30	–	–	﹤0.01%	455
2022 Q1	$2K	Buy	+30	New	+$1.56K	﹤0.01%	490

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Bellevue Asset Management's ITCI Position: Q1 2025 in Review

Bellevue Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 30 shares — an estimated $2.5K sold.

Bellevue Asset Management first reported a position in ITCI in Q1 2022 and held it in 12 quarters. The position peaked at $2.5K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Bellevue Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Bellevue Asset Management sold 30 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $2.5K.
Bellevue Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 12 quarters.
Bellevue Asset Management's Intra-Cellular Therapies Inc. position peaked at $2.5K in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Bellevue Asset Management's 13F filing for Q1 2025, filed 28 Apr 2025.